DNA damage response-initiated cytokine secretion in bone marrow stromal cells promotes chemoresistance of myeloma cells.
Tang H et al. Leuk Lymphoma. 2017 Dec 18:1-7. doi: 10.1080/10428194.2017.1413188. [Epub ahead of print].
Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
Zhou L et al. Br J Cancer. 2017 Dec 14. doi: 10.1038/bjc.2017.432. [Epub ahead of print].
Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells.
Muguruma Y et al. Blood Cancer J. 2017 Dec 15;7(12):650. doi: 10.1038/s41408-017-0001-3.
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.
Sanchez E et al. Target Oncol. 2017 Dec 11. doi: 10.1007/s11523-017-0538-x. [Epub ahead of print].
Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression.
Chen L et al. Cell Cycle. 2017 Dec 11:1-28. doi: 10.1080/15384101.2017.1407893. [Epub ahead of print].
C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis.
Yang J et al. Sci Signal. 2017 Dec 12;10(509). pii: eaan6282. doi: 10.1126/scisignal.aan6282.
Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
Allegra A et al. Toxicol In Vitro. 2017 Dec 6. pii: S0887-2333(17)30367-3. doi: 10.1016/j.tiv.2017.12.001. [Epub ahead of print].
Immunophenotypic and laboratory features of t(11;14)(q13;q32)-positive plasma cell neoplasms.
Shi M et al. Leuk Lymphoma. 2017 Dec 7:1-7. doi: 10.1080/10428194.2017.1410885. [Epub ahead of print].
The mechanism study of miR-125b in occurrence and progression of multiple myeloma.
Gao D et al. Cancer Med. 2017 Dec 7. doi: 10.1002/cam4.1181. [Epub ahead of print].
Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.
Ren Z et al. Blood. 2017 Dec 6. pii: blood-2017-07-797050. doi: 10.1182/blood-2017-07-797050. [Epub ahead of print].
Aberrant lncRNA Expression in Multiple Myeloma.
Meng H et al. Oncol Res. 2017 Dec 4. doi: 10.3727/096504017X15123872205507. [Epub ahead of print].
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
Maura F et al. Leukemia. 2017 Dec 6. doi: 10.1038/leu.2017.345. [Epub ahead of print].
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.
Bolli N et al. Leukemia. 2017 Dec 6. doi: 10.1038/leu.2017.344. [Epub ahead of print].
Cytogenetic Profiling of Myelomas, Association With Complete Blood Count: Study of 180 Patients.
Tarigopula A et al. Lab Med. 2017 Dec 1. doi: 10.1093/labmed/lmx066. [Epub ahead of print].
Restoration of the prolyl-hydroxylase domain protein-3 oxygen-sensing mechanism is responsible for regulation of HIF2α expression and induction of sensitivity of myeloma cells to hypoxia-mediated apoptosis.
Gastelum G et al. PLoS One. 2017 Dec 5;12(12):e0188438. doi: 10.1371/journal.pone.0188438. eCollection 2017.
LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway.
Wu Y et al. J Biochem Mol Toxicol. 2017 Dec 4. doi: 10.1002/jbt.22008. [Epub ahead of print].
Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma.
Lazzari E et al. Nat Commun. 2017 Dec 4;8(1):1922. doi: 10.1038/s41467-017-01890-w.
3D genome of multiple myeloma reveals spatial genome disorganization associated with copy number variations.
Wu P et al. Nat Commun. 2017 Dec 5;8(1):1937. doi: 10.1038/s41467-017-01793-w.
The proteasome and proteasome inhibitors in multiple myeloma.
Gandolfi S et al. Cancer Metastasis Rev. 2017 Dec;36(4):561-584. doi: 10.1007/s10555-017-9707-8.
Expressed fusion gene landscape and its impact in multiple myeloma.
Cleynen A et al. Nat Commun. 2017 Dec 1;8(1):1893. doi: 10.1038/s41467-017-00638-w.
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
de la Puente P et al. J Control Release. 2017 Nov 28. pii: S0168-3659(17)31052-0. doi: 10.1016/j.jconrel.2017.11.045. [Epub ahead of print].
Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance.
Danhof S et al. Haematologica. 2017 Nov 30. pii: haematol.2017.178947. doi: 10.3324/haematol.2017.178947. [Epub ahead of print].